医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Igenbio Establishes Direct Presence in Japan

2014年05月23日 AM01:46
このエントリーをはてなブックマークに追加


 

CHICAGO

Igenbio, Inc., a Chicago based genome analysis company, announced today the establishment of a representative office in Japan. Igenbio Japan will be promoting and distributing its flagship product, ERGO, the next generation Genome Analysis & Discovery System, to the Japanese market.

“Igenbio, Inc. has been experiencing growth on all fronts. We are excited to turn our attention to the Japanese life sciences market. We believe that our products align with the high-quality genomics and synthetic biology work being done in Japan,” said Vinayak Kapatral, President & CEO of Igenbio, Inc. “Having a Japan-focused and localized web channel supported by our local office will enable us to better serve our customer base in Japan.”

Japan has been a key area of opportunity for Igenbio. Inc, constituting one of the countries most focused on genomic research. “Having a local office will help Igenbio take up a strong position in this important market by showing our commitment to this extremely demanding customer base,” said Igenbio Japan CM Jaffer Hussainee, the newly appointed Country Manager for Igenbio Japan.

About Igenbio

Chicago-based Igenbio, Inc. specializes in research in microbial genomics, biochemistry, and gene expression. Igenbio, Inc. serves a broad customer base across industry, academic and government institutions. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data and tools for genome research. www.igenbio.com, Japanese website: www.igenbio.jp

CONTACT

Igenbio, Inc.
Vinayak Kapatral, Ph.D.
President, CEO
Tel:
(312) 733-8485 Ext 1
Fax: (312) 277-3478
E-mail: vinayak@igenbio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates